{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-098843","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.944932+00:00","generated_at":"2026-06-10T22:31:21.352705+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eloxx submits IND for ELX-02 in Alport syndrome; Phase 2 data show remission in 1 of 3 patients","bullets":["Submitted IND to FDA for ELX-02 to treat Alport syndrome with nonsense mutations.","Phase 2 open-label trial: Patient 4401-02 achieved remission with UPCR improving from 1,646 to 850 mg/g during treatment.","Two other patients (4401-01, 4402-01) did not achieve remission; UPCR increased post-treatment.","Data show on-treatment remission in one patient, confirming drug activity."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-098843","json":"https://secwatch.observer/filing/0001104659-23-098843.json","markdown":"https://secwatch.observer/filing/0001104659-23-098843.md","text":"https://secwatch.observer/filing/0001104659-23-098843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923098843/0001104659-23-098843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923098843/tm2325683d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:31:21.352705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}